Retisert

Retisert is a brand name of fluocinolone ophthalmic, approved by the FDA in the following formulation(s):

RETISERT (fluocinolone acetonide - implant; intravitreal)

• 
  Manufacturer: BAUSCH AND LOMB
  
  Approval date: April 8, 2005
  
  Strength(s): 0.59MG ^[RLD]

Has a generic version of Retisert been approved?

No. There is currently no therapeutically equivalent version of Retisert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Retisert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating and/or preventing retinal diseases with sustained release corticosteroids
  Patent 6,217,895
  Issued: April 17, 2001
  Inventor(s): Guo; Hong & Ashton; Paul
  Assignee(s): Control Delivery Systems
  The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
  
  Patent expiration dates:
  
  
  • March 22, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
    ✓ 
    Drug product
  
  



• 
  Method for treating and/or preventing retinal diseases with sustained release corticosteroids
  Patent 6,548,078
  Issued: April 15, 2003
  Inventor(s): Hong; Guo & Paul; Ashton
  Assignee(s): Control Delivery Systems
  The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
  
  Patent expiration dates:
  
  
  • March 22, 2019
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 8, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Retisert Consumer Information (Drugs.com)
• Retisert Implant Consumer Information (Wolters Kluwer)
• Retisert Consumer Information (Cerner Multum)
• Retisert eent AHFS DI Monographs (ASHP)
• Fluocinolone Acetonide Implant Consumer Information (Wolters Kluwer)
• Fluocinolone ophthalmic implant Consumer Information (Cerner Multum)
• Fluocinolone Acetonide eent AHFS DI Monographs (ASHP)